Syncona Limited (SYNC)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 127.40 |
|---|---|
| 52-week range | 86.80 – 131.80 |
| Return, 1 month / 3 months | +8.1% / +20.6% |
| Return, 1 year / 3 years | +26.9% / +1.4% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 20.1% |
| Worst drawdown (1 year) | -15.3% |
| Average daily value traded | 159.09M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Syncona Limited is a healthcare investment company based in the United Kingdom. It builds and supports life science businesses, concentrating on areas such as gene therapy and biotechnology, and works closely with founders and management teams to develop treatments for serious diseases. Its portfolio companies operate in the pharmaceutical and medical research fields, serving patients and healthcare systems. Syncona provides capital and long-term backing to these ventures, helping them advance their science from early stages toward clinical use.
Syncona Limited trades under the code SYNC on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Syncona Limited (SYNC) trades on the London Exchange in UK. It last closed at GBX 127.40 on 23 October 2026.
Its price-based Market X-Ray is 87 out of 100 (a strong price profile), ranking 1 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 26.9% and over the last three months it rose 20.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 23.9% | ||
| From 52-week high | -1.2% | ||
| Momentum | 83 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 20.6% | ||
| 6-month return | 45.8% | ||
| 12-month return, skipping the last month | 17.3% | ||
| Stability (higher is calmer) | 86 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 20.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.3% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 159.09M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −1.2% |
|---|---|
| 1 month | +8.1% |
| 3 months | +20.6% |
| 6 months | +45.8% |
| 1 year | +26.9% |
| 3 years | +1.4% |
| 5 years | −33.4% |
Signals
| 50-day / 200-day average | 117.40 / 102.83 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.80 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Jun 2019 | GBP 0.0230 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.